Bio/Pharma Business

Samsung Biologics to Build Plant 5 as Part of Capacity Expansion to Bio Campus II

March 21, 2023

Samsung Biologics plans to invest more than ₩1.9 trillion (US$1.5 billion) in the new Incheon, South Korea, facility, which will hold a manufacturing capacity of 180,000 L.

DCAT 2023 Highlights

March 20, 2023

Highlights from DCAT Week 2023, hosted from March 20 - March 25.

Genuv and Celltrion Partner on Development of Novel Therapeutic Antibodies

March 17, 2023

The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.

Pfizer to Acquire Seagen in $43 Billion Blockbuster Deal

March 16, 2023

Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.

Frontrunner in Microbiome Therapeutics

March 03, 2023

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.

Eli Lilly to Cap Out-Of-Pocket Insulin Costs at $35

March 02, 2023

Lilly will cap insulin prices for patients with and without insurance at $35 per month.

Subsurface Currents

March 02, 2023

That wave beginning to crash over PhRMA’s gunwales may well emanate from a startup mindset, rather than Big Pharma or government policy pundits.

AstraZeneca Strikes $1.16 Billion Licensing Deal for Gastric Cancer Candidate

March 01, 2023

AstraZeneca has entered into a global exclusive license agreement with KYM Biosciences for CMG901, which is being investigated as a gastric cancer treatment.

Moderna and Life Edit Therapeutics Enter Gene Editing Collaboration

February 24, 2023

Moderna will leverage Life Edit’s suite of gene editing technologies to advance development of in vivo gene editing therapies.

AbbVie and Capsida Strike $674 Million Gene Therapy Development Deal

February 24, 2023

AbbVie and Capsida have expanded their existing collaboration to advance three new gene therapy programs.